Comparative pharmacovigilance of herpetic infections with dupilumab and Janus kinase inhibitors in atopic dermatitis

杜皮鲁玛 医学 药物警戒 特应性皮炎 不良事件报告系统 不利影响 贾纳斯激酶 皮肤病科 Janus激酶抑制剂 食品药品监督管理局 安全概况 加药 药品 单纯疱疹病毒 临床试验 鲁索利替尼 单克隆 免疫学 梅德林 过敏 托法替尼 年轻人 内科学 斯科拉德
作者
Yaning Tian,Meixuan Li,Haoyang Hong,Rongfang Feng,Mai Luo,Yumin Xia
出处
期刊:Clinical and Experimental Dermatology [Oxford University Press]
卷期号:51 (11): 2051-2059
标识
DOI:10.1093/ced/llag242
摘要

BACKGROUND: Targeted systemic therapies for atopic dermatitis (AD), including biologics and Janus kinase inhibitors, are increasingly used. However, comparative postmarketing evidence on herpetic infection-related safety signals across these therapies remains limited. OBJECTIVES: To compare safety signals of herpetic infections associated with targeted AD therapies using the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: FAERS reports (Q2 2017 to Q1 2025) involving dupilumab, abrocitinib, baricitinib or upadacitinib were included if these agents were designated as the primary suspect drug and the indication was AD. Disproportionality analyses using four algorithms were performed to detect signals for overall and virus-specific herpetic events. Subgroup analyses by age, sex and time to onset (TTO) were conducted. RESULTS: All therapies demonstrated positive signals for herpetic infections. Baricitinib and abrocitinib showed the strongest signals, followed by upadacitinib, whereas dupilumab showed comparatively lower signals overall. Notably, dupilumab demonstrated a herpes simplex virus (HSV) signal comparable with abrocitinib and higher than for upadacitinib, and a signal for eczema herpeticum (EH) was also identified. Signals were generally higher in female patients, except for upadacitinib. Age-stratified analyses showed varying signal patterns across age groups. The median TTO differed between therapies, with an earlier onset for upadacitinib. CONCLUSIONS: Reporting patterns of herpetic infections differ across targeted AD therapies. Disproportionate reporting of HSV and EH with dupilumab warrants further investigation. Differences across sex, age and TTO suggest potential heterogeneity in reporting patterns, which may reflect underlying patient characteristics and reporting behaviours.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.3的应助被Marshall采纳,获得10
1秒前
1秒前
2秒前
整齐的寄松完成签到,获得积分10
2秒前
My_magnum_opus的应助被master采纳,获得30
4秒前
lyb关闭了lyb的文献求助
5秒前
ku发布了新的文献求助10
5秒前
无奈冬瓜发布了新的文献求助10
6秒前
6秒前
6秒前
触手可及的珩星完成签到 ,获得积分10
7秒前
Ava的应助被任江归采纳,获得10
7秒前
7秒前
浮云客发布了新的文献求助10
8秒前
桐桐的应助被周周采纳,获得10
9秒前
蝴蝶兰发布了新的文献求助10
11秒前
无敌的ybk发布了新的文献求助10
11秒前
琪琪完成签到,获得积分10
12秒前
赘婿的应助被啊嘞哇塞采纳,获得10
13秒前
志小天完成签到,获得积分10
13秒前
13秒前
15秒前
17秒前
阿姆逗完成签到 ,获得积分10
17秒前
18秒前
18秒前
欧拉不拉完成签到,获得积分10
19秒前
俏皮诺言发布了新的文献求助10
19秒前
喔喔某人完成签到,获得积分10
19秒前
zho发布了新的文献求助10
19秒前
乐乐的应助被后笑晴采纳,获得10
20秒前
尔尔完成签到,获得积分10
21秒前
21秒前
zalll完成签到 ,获得积分10
22秒前
22秒前
23秒前
任江归发布了新的文献求助10
24秒前
25秒前
26秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183601
求助须知:如何正确求助?哪些是违规求助? 9572875
关于积分的说明 21827816
捐赠科研通 7780716
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558197
邀请新用户注册赠送积分活动 2480485